Last March, a guy named Derek in Scottsdale told me he'd been pinning AOD 9604 subcutaneously for six weeks. He was 41, about 215 pounds, and running a 400-calorie daily deficit with three days a week of lifting. "I've lost maybe four pounds," he said, "but my waist is down an inch and a half. My trainer measured it twice because she didn't believe it." He paused. "Is that the peptide or is that just the diet finally working?" Honest answer: probably both, and there's no clean way to separate them.
That ambiguity sits right at the center of everything worth saying about AOD 9604 and weight loss. The peptide does something real. The question is whether that something is big enough to matter for you, specifically, given the alternatives available in 2024.
Where AOD 9604 Came From (and Why It Stalled)
Researchers at Monash University in Australia developed AOD 9604 in the 1990s with a clever premise: isolate the fat-burning signaling fragment of human growth hormone (amino acids 177-191, plus a tyrosine) while ditching the messy endocrine side effects of full-length HGH. No IGF-1 spikes. No fluid retention. No glucose dysregulation. Just lipolysis.
Metabolic Pharmaceuticals, an Australian biotech, picked it up and carried it into clinical development. By 2007 they had completed a Phase 2b trial. And then, quietly, the program died.
Not because the peptide was dangerous. Because it wasn't impressive enough.
The Only Real Clinical Trial We Have
The 2007 Phase 2b trial is the anchor of every honest conversation about AOD 9604 for weight loss. Here's what it looked like:
534 obese participants. Randomized, double-blind, placebo-controlled. Four dose arms (1 mg, 5 mg, 10 mg, and 30 mg oral) against placebo, measured over 12 weeks. The primary endpoint was weight loss.
The results were odd. The 1 mg dose arm showed statistically significant weight loss compared to placebo. But the absolute magnitude was modest. And then the really strange part: higher doses didn't work better. The 5, 10, and 30 mg arms showed no proportional advantage. The dose-response curve was flat, or worse.
On the safety side, things looked clean. IGF-1 didn't budge. Glucose and insulin parameters stayed stable. Tolerability was good. The mechanistic thesis held up perfectly. AOD 9604 did exactly what they designed it to do: trigger lipolytic signaling through beta-3 adrenergic receptor activation without activating the GH receptor.
The problem was scale. When your drug produces a real but small weight loss signal in a 12-week trial, and cranking the dose higher doesn't help, that's a tough sell to the FDA for Phase 3 funding. Metabolic Pharmaceuticals walked away.
What That Trial Actually Tells Us
I think people get into trouble with AOD 9604 because they read the wrong conclusion from that study. The wrong conclusion is "it doesn't work." The right conclusion is more specific: it works, but not enough to function as a standalone obesity drug.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Here's what the evidence genuinely supports:
Lipolytic signaling is real. In vitro, in animal models, and in the human trial, AOD 9604 triggers fat release from adipocytes. This isn't speculative.
It doesn't act like HGH where you don't want it to. No IGF-1 elevation, no glucose problems, no water retention at studied doses. The whole point was a clean safety profile, and they got it.
Tolerability is a non-issue at the doses that have been studied. Side effects in the trial were basically limited to injection/administration site reactions.
The weight loss signal, while statistically significant, was small. If you're looking for the kind of results semaglutide or tirzepatide produce (15-20%+ body weight in some trials), AOD 9604 is playing a completely different sport.
And here's what the evidence does not support, no matter what you've read on Reddit or seen in a TikTok transformation reel:
Escalating the dose for bigger results. The trial tested this explicitly. It didn't work. More is not more with this peptide.
Using AOD 9604 as your primary weight loss intervention. The effect size doesn't justify that framing. Period.
Predicting who will respond well. The pre-treatment factors that separate responders from non-responders haven't been characterized. Derek in Scottsdale noticed something. Plenty of other people running the same protocol notice nothing.
So Who Is This Actually For?
Think of AOD 9604 less like a weight loss drug and more like a metabolic tailwind. It's the difference between cycling into a headwind and cycling on a calm day. You still have to pedal.
The people who seem to get the most out of it (anecdotally, because we don't have great long-term data) are the ones already doing the fundamentals: caloric deficit, structured exercise, decent sleep, managed stress. For those people, AOD 9604 may offer a modest additional lipolytic push. Body composition shifts (think: waist measurements, how clothes fit, mirror changes) rather than dramatic drops on the scale.
The timeline matters too. The Phase 2b trial measured outcomes at 12 weeks. If you're evaluating AOD 9604 after three weeks and seeing nothing, that doesn't necessarily mean it's failing. But it does mean patience is part of the protocol.
Let me be direct about one thing: if you have significant obesity and would qualify for FDA-approved pharmacotherapy (GLP-1 agonists like semaglutide or the dual GIP/GLP-1 agonist tirzepatide), those medications will almost certainly produce larger, more reliable results. The effect size gap between AOD 9604 and modern obesity drugs is enormous. Choosing AOD 9604 over those options because it feels more "natural" or because you want to avoid a mainstream prescription is, in most cases, choosing a worse tool for the job.
Combination Protocols: The Stacking Question
Clinicians and self-experimenters often stack AOD 9604 with other peptides on the logic that complementary mechanisms might add up. The most common combinations:
AOD 9604 plus Tesamorelin. This pairs targeted lipolytic signaling with stimulated endogenous GH release. Tesamorelin has FDA approval for HIV-associated lipodystrophy and carries the strongest fat-reduction data of any GH-releasing peptide, though in a specific patient population.
AOD 9604 plus Sermorelin. A milder stack. Sermorelin is a 29-amino-acid GHRH analog with broader physiological GH release effects. Less potent than Tesamorelin but more widely prescribed in compounding contexts.
AOD 9604 alongside GLP-1 medications. This is a prescriber decision, not a formal protocol. The mechanisms don't overlap (appetite suppression and metabolic signaling from the GLP-1 side, lipolytic signaling from AOD 9604), which makes the theoretical case for combination reasonable. But there's no published research on the pairing, so you're in uncharted territory.
None of these combinations have been studied in controlled trials specifically for the stacked configuration. That doesn't mean they're dangerous. It means you and your prescriber are making an educated guess.
The Boring Truth About Weight Loss and Peptides
Caloric deficit is still the engine. Exercise is the multiplier. Sleep and stress management are the conditions that let both of those things actually work (through cortisol regulation, insulin sensitivity, and a dozen other overlapping pathways).
AOD 9604 doesn't replace any of that. It's a layer. For some people, it appears to be a useful layer. For others, it's an expensive placebo. The honest position is that we don't have the data quality to tell you with confidence which group you'll fall into before you try it.
The catch is that the peptide space often sells AOD 9604 as something it isn't. It's not a fat-loss breakthrough. It's a fragment peptide with a confirmed mechanism, a modest clinical signal, and an abandoned development program. That's the full picture.
Frequently Asked Questions
How much weight can I lose on AOD 9604?
The Phase 2b trial showed statistically significant but modest weight loss over 12 weeks at the 1 mg oral dose. Nobody should be quoting you specific pound figures as guaranteed outcomes. Individual variability is high, and the trial's effect sizes were small enough that Metabolic Pharmaceuticals chose not to pursue Phase 3 development.
Is AOD 9604 better than diet and exercise?
No. It's not a substitute. The clinical evidence describes it as producing an additive signal within a normal lifestyle context. Without caloric deficit and physical activity, there's no reason to expect meaningful results from AOD 9604 alone.
How long do I need to take AOD 9604 to see results?
The clinical trial measured outcomes at 12 weeks. Most practitioners recommend evaluating over at least an 8 to 12 week cycle before drawing conclusions.
Should I combine AOD 9604 with semaglutide?
That's a conversation for your prescriber, not the internet. The mechanisms are non-overlapping, which makes the theoretical rationale reasonable, but there's no published research on the combination. Your medical history, current medications, and weight loss goals all factor into whether it makes sense.
Why isn't AOD 9604 FDA-approved for weight loss?
Because the Phase 2b trial, while confirming the mechanism, didn't produce effect sizes large enough to justify the cost and timeline of Phase 3 development. The sponsor made a business decision, not a safety decision.
Does AOD 9604 affect blood sugar or insulin?
In the Phase 2b trial, glucose and insulin parameters were not significantly affected. This is consistent with AOD 9604's design as a fragment that avoids GH receptor activation.
Is AOD 9604 safe?
The clinical trial data shows a favorable tolerability profile at studied doses. Side effects were minimal beyond administration site reactions. That said, long-term safety data from large populations doesn't exist because the development program ended after Phase 2b.
Related Reading
- AOD 9604 Hub
- AOD 9604 Dosage Protocols
- AOD 9604 Benefits and Research
- AOD 9604 versus HGH
- AOD 9604 versus Tesamorelin for Fat Loss
Compliance Footer
AOD 9604 is not approved by the FDA for the prevention, mitigation, treatment, or cure of any disease, including obesity or weight loss. Compounded AOD 9604 is prepared by licensed compounding pharmacies for individual patients under a valid prescription from a licensed prescriber. Information on this page is educational and is not medical advice. Individual results vary.